Jack Lief's Projections for 2015 vs. Reality  --- this is the kind of Bullshit that the terrible past CEO, Jack Lief & his gang, fed investors. Thank God he got fired ("asked to retire") by the Board.

“This year is shaping up to be a especially interesting year for Arena -- this presentation will illustrate our clear focus on building shareholder value.” Jack Lief, January 14th, 2015 at J.P. Morgan Healthcare Conference [stock was $6.13 vs. $1.90 by year end 2015!]

”As investors and people will see this year we're basically with our pipeline advancing into phase 2 programs we're basically a completely different company than we were viewed as last year… The demand for exciting new drugs is SUBSTANTIAL (with emphasis) in the market. We've seen that since we announced 334 data - we have interest in all of our pipeline products with other companies.“ Jack Lief, February 24, 2015, RBC Capital Markets [stock was $4.74 vs. $1.90 by year end 2015!]

”We are optimistic about opportunities to create additional value, both through continued growth in BELVIQ sales and through our development programs. We believe the intrinsic value of our development program assets will increase significantly in 2015, as we advance our candidates in multiple late-stage clinical trials, file an NDA for our QD lorcaserin formulation and report additional clinical data...” Jack Lief, March 2, 2015, Earnings Call [stock was $4.50 vs. $1.90 by year end 2015!]

"So by the end of next year, based on our current expectations for patient accruals, we expect to have readouts on five programs associated with different diseases, anything from pulmonary artery hypertension to ulcerative colitis, looking at thrombosis, looking at pain and looking at psychosis. So, all of these are really addressing unmet medical needs." Jack Lief, September 9, 2015 Wells Fargo Healthcare Conference [stock was $2.76 vs. $1.90 by year end 2015 and the readout timing projections for 2016 turned out to be bullshit].

"there are a number of other markets that are expected to launch in the not too distant future and that’s going to help prescriptions as well." Jack Lief, September 9, 2015 Wells Fargo Healthcare Conference [stock was $2.76 vs. $1.90 by year end 2015 -- and no new launch was announced for a very long time, if ever, since that date].

2015 closing price of ARNA: $1.90